Abstract
The evolution of antiretroviral drug resistance is a major problem in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Drug therapy failure is associated with accumulation of drug resistance mutations and results in the development of drug resistance. Drugs targeted against reverse transcriptase (RT) as well as drug-resistant RT have been shown to increase HIV-1 mutation frequencies. Furthermore, combinations of drug and drug-resistant RT can increase virus mutation frequencies in a multiplicative manner. The evolution of drug resistance also alters virus fitness. The correlation of increased HIV-1 mutation rates with the evolution of antiretroviral drug resistance indicates that drug failure could increase the likelihood of further resistance evolving from subsequent drug regimens. These observations parallel studies from microbial systems that provide evidence for a correlation between drug resistance development and increased pathogen mutation rates. Although increased mutan t frequencies may be detrimental to effective therapy, the lethal mutagenesis of the HIV-1 genome may provide a new means for antiretroviral therapy.
Keywords: hiv infection, nucleoside reverse, transcriptase inhibitors, protease inhibitors, replication cycle, genomes, antiretroviral drugs, azt-resistant virus, mutagenesis, antimicrobial drug
Current Pharmaceutical Design
Title: Drug Resistance, Virus Fitness and HIV-1 Mutagenesis
Volume: 10 Issue: 32
Author(s): Renxiang Chen, Miguel E. Quinones-Mateu and Louis M. Mansky
Affiliation:
Keywords: hiv infection, nucleoside reverse, transcriptase inhibitors, protease inhibitors, replication cycle, genomes, antiretroviral drugs, azt-resistant virus, mutagenesis, antimicrobial drug
Abstract: The evolution of antiretroviral drug resistance is a major problem in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Drug therapy failure is associated with accumulation of drug resistance mutations and results in the development of drug resistance. Drugs targeted against reverse transcriptase (RT) as well as drug-resistant RT have been shown to increase HIV-1 mutation frequencies. Furthermore, combinations of drug and drug-resistant RT can increase virus mutation frequencies in a multiplicative manner. The evolution of drug resistance also alters virus fitness. The correlation of increased HIV-1 mutation rates with the evolution of antiretroviral drug resistance indicates that drug failure could increase the likelihood of further resistance evolving from subsequent drug regimens. These observations parallel studies from microbial systems that provide evidence for a correlation between drug resistance development and increased pathogen mutation rates. Although increased mutan t frequencies may be detrimental to effective therapy, the lethal mutagenesis of the HIV-1 genome may provide a new means for antiretroviral therapy.
Export Options
About this article
Cite this article as:
Chen Renxiang, Quinones-Mateu E. Miguel and Mansky M. Louis, Drug Resistance, Virus Fitness and HIV-1 Mutagenesis, Current Pharmaceutical Design 2004; 10 (32) . https://dx.doi.org/10.2174/1381612043382404
DOI https://dx.doi.org/10.2174/1381612043382404 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibacterial Effects of Carbon Monoxide
Current Pharmaceutical Biotechnology Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design An Overview on Chemistry and Biological Importance of Pyrrolidinone
Current Organic Synthesis Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective
Current Rheumatology Reviews Interaction Mechanisms of Inorganic Nanoparticles and Biomolecular Systems of Microorganisms
Current Chemical Biology Lipid-Specific Immune Responses Against Tuberculosis: From Basic Science to Medical Applications
Current Immunology Reviews (Discontinued) Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 1: General Overview with a Focus on Ascorbic Acid
Inflammation & Allergy - Drug Targets (Discontinued) Tuberculous Lymphadenitis in Southern Italy: Clinical Aspects and Treatment Perspectives
Anti-Infective Agents Bis(2-aminoimidazolines) and Bisguanidines: Synthetic Approaches, Antiparasitic Activity and DNA Binding Properties
Current Medicinal Chemistry Shikimate Kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: Kinetics and Structural Dynamics of a Potential Molecular Target for Drug Development
Current Medicinal Chemistry Treatment Discontinuation in Adult HIV-Infected Patients on First-Line Antiretroviral Therapy in Nigeria
Current HIV Research Modern Approach to Medical Diagnostics - the Use of Separation Techniques in Microorganisms Detection
Current Medicinal Chemistry Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Treatment of Opportunistic Infections Prior to HAART Initiation Does Not Affect Immune Reconstitution in HIV-Infected Patients
Current HIV Research Disseminated TB in an Immunocompetent Patient: A Case Report
Infectious Disorders - Drug Targets Short Antimicrobial Peptides
Recent Patents on Anti-Infective Drug Discovery Dubious Results of Remdisivir Ultimately in Solidarity; Diversity of Severity of Illness is Doubtful
New Emirates Medical Journal Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review
Protein & Peptide Letters